Prostamax
Lys-Glu-Asp-Pro (KEDP)
Prostamax appears in an experimental ex-vivo peptide study; no clinical prostate treatment was studied.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
The cited primary study defines the tested Prostamax as Lys-Glu-Asp-Pro. It is not interchangeable with Prostatilen or prostate extracts and does not validate a commercial lot.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The source treated leukocytes from older donors outside the body and examined several short peptides.
- Effects of short peptides on lymphocyte chromatin in senile subjectsLaboratory study2004
Khavinson VKh; Lezhava TA; Malinin VV
Accessed:
Research gaps
- ·The name and a chromatin finding do not establish organ-specific efficacy. Clinical prostate endpoints and independent replication are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Researchers measured chromatin changes in cultured lymphocytes, not a prostate-specific receptor or clinical mechanism.
- Effects of short peptides on lymphocyte chromatin in senile subjectsLaboratory study2004
Khavinson VKh; Lezhava TA; Malinin VV
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Human exposure, pharmacokinetics, toxicology, contraindications and interactions have not been adequately studied.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·The name and a chromatin finding do not establish organ-specific efficacy. Clinical prostate endpoints and independent replication are absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Effects of short peptides on lymphocyte chromatin in senile subjectsLaboratory study2004
Khavinson VKh; Lezhava TA; Malinin VV
Accessed:
Sources
Sources checked: · Version 3
- Effects of short peptides on lymphocyte chromatin in senile subjectsLaboratory study2004
Khavinson VKh; Lezhava TA; Malinin VV
Accessed: